International Journal of ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P15
ISSN: 2319-9253

AI-POWERED COMPUTATIONAL ONCOLOGY: ADVANCING PERSONALIZED CANCER MEDICINE THROUGH MULTIMODAL DATA FUSION

[#1] **Dr. Arjun Menon**, Associate Professor, Department of Surgery,
Father Muller Medical College, Mangaluru, India
Arjunmenon46@gmail.com

[#2] **Dr. Roshni Sharma**, Assistant Professor, Department of Pathology,
Father Muller Medical College, Mangaluru, India
Roshnisharma34@gmail.com

[#3] **Mrs. Shilpa Rao**, Assistant Professor, Department of Anatomy,
Father Muller Medical College, Mangaluru, India
Shilparao67@gmail.com

[#4] **Dr. Danish Khan**, Professor, Department of Radiology,
Father Muller Medical College, Mangaluru, India
Danishkhan82@gmail.com

Abstract: Computational oncology is undergoing a transformative evolution through the integration of artificial intelligence (AI), multimodal biomedical data fusion, and precision medicine into intelligent computational ecosystems capable of supporting personalized cancer care throughout the disease continuum. Conventional oncology frequently relies on fragmented interpretation of imaging, pathology, molecular diagnostics, and clinical information, thereby limiting comprehensive understanding of the complex biological mechanisms governing tumor evolution and therapeutic response. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, and generative artificial intelligence have enabled unified analysis of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes. These intelligent computational systems support early cancer detection, molecular characterization, biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen computational oncology by enabling collaborative, privacy-preserving, and continuously adaptive biomedical intelligence. Despite remarkable technological progress, significant scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interpretability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of AI-powered computational oncology, emphasizing multimodal data fusion as a transformative framework for advancing personalized cancer medicine.[1]

Keywords: *Computational oncology, Artificial intelligence, Precision oncology, Foundation models, Multimodal learning, Multi-omics, Digital pathology, Radiomics, Clinical decision support, Personalized medicine.*

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and complex interactions among malignant cells, stromal components, immune populations, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern healthcare generates unprecedented volumes of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently fails to capture systems-level relationships governing disease progression, therapeutic response, resistance mechanisms, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Foundation AI models extend these capabilities through generalized multimodal learning that enables transfer of computational knowledge across numerous oncology applications while continuously adapting to evolving biomedical evidence.

The convergence of computational oncology and multimodal artificial intelligence therefore establishes a transformative paradigm capable of supporting personalized precision medicine throughout the cancer care continuum.[4]

2. Evolution of AI-Powered Computational Oncology

Computational oncology has evolved from conventional statistical analyses toward intelligent biomedical ecosystems capable of continuously learning from diverse healthcare data. Early computational methods primarily relied upon handcrafted feature engineering and machine learning algorithms developed for isolated diagnostic or prognostic tasks. Although these systems demonstrated important clinical value, they remained constrained by fragmented biomedical information, limited adaptability, and narrow task specialization.[5]

Deep learning substantially advanced computational oncology through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Foundation AI models have now transformed computational oncology through large-scale self-supervised pretraining capable of generating transferable biomedical knowledge applicable across diagnosis, prognosis, biomarker discovery, therapeutic prediction, disease monitoring, radiomics, pathomics, genomics, and intelligent clinical decision support.[6]

3. Principles of Multimodal Data Fusion

Multimodal data fusion represents the computational foundation of AI-powered oncology because it enables integration of heterogeneous biomedical information into unified patient-specific representations. Foundation AI models acquire generalized biomedical knowledge from radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories before adaptation to specialized oncology applications.[7]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align diverse biomedical modalities within shared computational embedding spaces. Graph neural networks further characterize interactions among genes, proteins,

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes.

These computational principles establish adaptive biomedical intelligence capable of supporting predictive precision oncology across the entire patient journey.[8]

4. Computational Architecture

Modern AI-powered computational oncology platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, representation learning, multimodal fusion, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[9]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. These unified computational representations support diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive learning, and personalized oncology.[10]

5. Radiomics and Imaging Intelligence

Radiomics transforms conventional medical imaging into quantitative biological information describing tumor morphology, texture, vascularity, metabolism, spatial heterogeneity, and temporal evolution. Foundation AI models automatically extract generalized imaging representations from computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, and hybrid imaging platforms without requiring handcrafted feature engineering.[11]

Artificial intelligence identifies latent imaging biomarkers associated with molecular alterations, immune infiltration, angiogenesis, fibrosis, hypoxia, therapeutic responsiveness, treatment resistance, and disease progression. Integration of radiomics with molecular biology and clinical intelligence substantially improves diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, and longitudinal disease monitoring.

These imaging representations provide a non-invasive computational window into evolving tumor biology while strengthening personalized oncology throughout the patient journey.[12]

6. Digital Pathology and Molecular Intelligence

Digital pathology has transformed oncological diagnosis by enabling computational analysis of whole-slide images containing billions of cellular structures. Foundation AI models extract generalized pathomic representations describing cellular morphology, tissue architecture, stromal remodeling, angiogenesis, fibrosis, necrosis, immune infiltration, and spatial cellular organization across diverse tumor types.[13]

Integration of pathomics with genomics, transcriptomics, proteomics, metabolomics, epigenomics, and spatial biology allows artificial intelligence to identify latent biological relationships linking microscopic tissue architecture with molecular alterations and therapeutic response.

These integrated molecular representations substantially improve biomarker discovery, prognostic prediction, therapeutic optimization, and systems-level understanding of cancer biology.[14]

7. Clinical Intelligence Through Electronic Health Records

Electronic health records provide one of the richest longitudinal sources of clinical information available in modern oncology. Structured laboratory investigations, medication history, pathology reports, treatment timelines, physician documentation, hospitalizations, patient-reported

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

International Journal of ADVANCED RESEARCH & INNOVATIONS
Volume 14, Issue-12
December, 2024, P15
ISSN: 2319-9253

outcomes, and survivorship information collectively provide comprehensive patient-level context extending beyond molecular diagnostics.[15]

Foundation AI models employ natural language processing, temporal transformers, and multimodal reasoning architectures to integrate structured and unstructured EHR data with radiological imaging, digital pathology, molecular biology, laboratory biomarkers, and physiological monitoring into unified patient-specific computational representations.

These comprehensive clinical embeddings substantially improve prognostic prediction, recurrence surveillance, toxicity estimation, therapeutic optimization, survivorship management, and evidence-based clinical decision-making.[16]

8. Multi-Omics Integration

Comprehensive computational oncology increasingly depends upon integration of genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, spatial biology, and single-cell sequencing into unified molecular representations of evolving tumor biology.[17]

Foundation AI models utilize multimodal transformers, graph neural networks, biological knowledge graphs, and self-supervised learning to identify latent biological relationships among genes, proteins, metabolites, signaling pathways, immune responses, imaging phenotypes, and clinical outcomes that remain difficult to detect using isolated analytical approaches.

These integrated molecular representations substantially improve biomarker discovery, molecular subtype classification, therapeutic response prediction, systems biology research, and individualized precision medicine.[18]

9. Predictive Precision Oncology

One of the most clinically important applications of AI-powered computational oncology is precision diagnosis and therapeutic prediction through comprehensive integration of radiomics, digital pathology, multi-omics, laboratory biomarkers, wearable physiological monitoring, physician documentation, and longitudinal clinical trajectories. Foundation AI models simultaneously analyze heterogeneous biomedical information to predict responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while estimating treatment-related toxicity, recurrence probability, progression-free survival, overall survival, and mechanisms of therapeutic resistance. These adaptive computational systems support individualized therapeutic planning while continuously refining predictive accuracy using newly acquired biomedical evidence throughout the cancer care continuum.[19][20]

10. Digital Twins and Virtual Patient Modeling

Digital twin technology represents one of the most transformative applications of AI-powered computational oncology by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]

Unlike conventional predictive models, digital twins continuously update their computational representations as new biomedical information becomes available. These intelligent virtual patients enable clinicians to evaluate multiple therapeutic strategies before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.

By combining multimodal biomedical intelligence with predictive simulation, digital twins transform computational oncology from retrospective analysis toward proactive precision medicine supported by continuously adaptive virtual patient ecosystems.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

Volume 14, Issue-12
December, 2024, P15
ISSN: 2319-9253

11. Intelligent Clinical Decision Support

AI-powered computational oncology provides the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, foundation AI models synthesize these diverse biomedical information sources into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Computational Intelligence

A defining characteristic of AI-powered computational oncology is its ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Consequently, computational oncology platforms remain synchronized with evolving tumor biology, emerging scientific discoveries, changing clinical guidelines, and diverse patient trajectories. This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized precision medicine.

13. Federated AI Networks for Computational Oncology

Development of highly generalizable AI-powered computational oncology platforms requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated computational oncology ecosystems therefore establish international collaborative networks capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible biomedical data stewardship.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

Volume 14, Issue-12
December, 2024, P15
ISSN: 2319-9253

14. Explainability, Validation, and Ethical Governance

Successful implementation of AI-powered computational oncology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the radiomic, pathomic, genomic, physiological, and clinical variables contributing to predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon protection of patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of intelligent computational systems into routine oncology practice.

15. Future Perspectives

Future computational oncology ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, and cloud-native healthcare infrastructure into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

AI-powered computational oncology represents one of the most significant paradigm shifts in precision medicine by integrating radiomics, digital pathology, multi-omics, electronic health records, laboratory biomarkers, wearable technologies, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, these intelligent frameworks simultaneously analyze molecular biology, tissue architecture, imaging phenotypes, laboratory biomarkers, physiological monitoring, environmental influences, and longitudinal clinical trajectories to generate holistic computational representations of evolving cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of multimodal artificial intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1215

As biomedical knowledge and healthcare data continue to expand exponentially, AI-powered computational oncology is expected to become the central computational infrastructure supporting personalized cancer medicine worldwide.

17. Conclusion

AI-powered computational oncology is transforming personalized cancer medicine by integrating radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and individualized clinical decision-making throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen intelligent computational oncology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical intelligence, adaptive therapeutics, continuous disease surveillance, and continuously personalized precision oncology.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of AI-powered computational oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
3. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
4. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
5. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
6. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
7. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
8. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
9. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
10. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer

Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
11. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
12. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
13. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
14. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
15. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
16. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
17. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
18. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
19. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
20. 20. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
21. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
22. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
23. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
24. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
25. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
26. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2

(2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345, DOI: https://doi.org/10.46121/pspc.52.2.18
27. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388, DOI: https://doi.org/10.46121/pspc.51.4.7
28. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
29. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343, DOI: https://doi.org/10.46121/pspc.52.4.16
30. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.